To the editor:
The recent editorial regarding drug pricing and the current laws that prohibit the U.S. government from negotiating for better pricing was deceiving. The author was correctly identified as Blanche Lincoln, a former U.S. senator from Arkansas. While true, the footer failed to also tell the reader that she is now the president of Lincoln Policy Group, whose recent clients have been drug manufacturers and marketers Pfizer and AbbVie, and insurance company Aetna. Thus, the reason her piece read as though it advocated a drug company perspective is that it was paid for by drug companies. Drug company perspectives are welcome to these debates, but readers should be made aware of where the money comes from.